Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ
Cabaser 1 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White, oval, 3.8 × 7.4 mm and both sides concave with one side scored and engraved ‘7’ on the left and ‘01’ on the right. |
1mg of cabergoline.
Excipient(s) with known effect:
Each tablet contains 75.4 mg of lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cabergoline |
Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity. |
| List of Excipients |
|---|
|
Lactose |
Class I amber glass bottles, stoppered with an aluminium tamper-evident screw cap equipped with a low density polyethylene/thermoplastic elastomer (LDPE/TPE) plastic undercap acting as a container holding silica gel, closed by a plastic cap with a porous paper at the lower extremity.
Or
White high-density polyethylene (HDPE) bottles with a child-resistant polypropylene (PP) cap equipped with inner low-density polyethylene (LDPE) desiccant canister containing silica gel.
Each bottle contains 20 or 30 tablets and is enclosed in an outer cardboard carton.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ
PL 00057/0936
14 February 1996
| Drug | Countries | |
|---|---|---|
| CABASER | Australia, Finland, Ireland, Japan, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
